Інсулінорезистентність як складова патогенезу артеріальної гіпертензії (огляд літератури)

S. V. Biletskyi

Анотація


Описано механізми формування інсулінорезистентності та її значення в патогенезі артеріальної гіпертензії.


Ключові слова


артеріальна гіпертензія; інсулінорезистентність; дисфункція ендотелію; пероксидне окиснення ліпідів

Повний текст:

PDF

Посилання


Alisheva EK, Krasil'nikova EI, Shlyakhto EV. Metody diagnostiki insulinorezistentnosti [Methods of diagnostics of insulin resistance]. Arterial. gipertoniya. 2002;1:29-33. (in Russian).

Babak OYa, Andreeva AO. Hormonal'ni zminy v zhyroviy tkanyni khvorykh na hipertonichnu khvorobu y ozhyrinnya [Hormonal changes in adipose tissue of patients with hypertension and obesity]. Ukr. terapevt. zh. 2013;1:63-7. (in Ukrainian).

Bilovol OM, Shalimova AS, Kochuyeva MM. Komorbidnist' hipertonichnoyi khvoroby ta tsukrovoho diabetu 2 typu – aktual'na problema suchasnoyi medytsyny [Komorbidnist hypertension and type 2 diabetes - a burning issue today medicine]. Ukr. terapevtych. zhurnal. 2014;1:11-7. (in Ukrainian).

Bratus' VV, Talaeva TV, Shumakov VA. Ozhirenie, insulinorezistentnost', metabolicheskiy sindrom: fundamental'nye i klinicheskie aspekty [Obesity, insulin resistance, metabolic syndrome: fundamental and clinical aspects]. Kiev: Chetverta khvilya; 2009. 416 p. (in Russian).

Miloslavskiy DK, Snegurskaya IA, Litvinova ON. Geneticheskie markery pri essentsial'noy arterial'noy gipertenzii, assotsiirovannoy s proyavleniyami metabolicheskogo sindroma [Genetic markers with essential arterial hypertension associated with manifestations metabolic syndrome]. Medytsyna s'ohodni i zavtra. 2010;2-3:99-107. (in Russian).

Kovaleva ON, Ambrosova TN. Metabolicheskiy sindrom kak factor riska serdechno-sosudistykh zabolevaniy [Metabolic syndrome as a factor risk of cardiovascular disease]. Praktychna anhiolohiya. 2008;3:28-30. (in Russian).

Man'kovskiy BN. Insulinorezistentnost': mekhanizmy formirovaniya i vozmozhnye puti korrektsii [Insulin resistance: mechanisms of formation and possible ways of correction]. Ratsional. farmakoterapiya. 2007;1:35-8. (in Russian).

Man'kovskiy BN. Novoe rukovodstvo po lecheniyu sakharnogo diabeta 2 tipa – chto izmenilos', v chem znachenie dlya klinicheskoy praktiki? [New treatment guide type 2 diabetes mellitus - what has changed, what value for clinical practice?]. Diabet. Ozhirenie. Metabolicheskiy sindrom. 2012;1:31-6. (in Russian).

Mel'nichenko GA, Pyshnina EA. Ozhirenie i insulinorezistentnost' – faktory riska i sostavnaya chast' metabolicheskogo sindroma [Obesity and insulin resistance are risk factors and an integral part of the metabolic syndrome]. Terapevticheskiy arkhiv. 2001;12:5-8. (in Russian).

Mychka VB, Chazova IE. Medikamentoznaya korrektsiya narusheniy uglevodnogo obmena: snizhenie riska serdechno-sosudistykh oslozhneniy medication correction of disorders [Carbohydrate metabolism: reducing the risk of cardiovascular complications]. Available from: http: //medi.ru/doc/ 260906.htm (15.11.2009). (in Russian).

Petrynych OA, Bilets'kyy SV, Mel'nychuk LV. Osoblyvosti metabolichnykh porushen' u khvorykh na hipertonichnu khvorobu ta v poyednanni z tsukrovym diabetom 2-ho typu: zv’yazok z insulinorezystentnistyu [Features of metabolic disorders in patients with hypertension and in combination with type 2 diabetes: association with insulin resistance]. Buk. med. visnyk. 2009;13(3):61-5. (in Ukrainian).

Petrynych OA. Osoblyvosti metabolichnykh pokaznykiv u khvorykh na hipertonichnu khvorobu ta v poyednanni z tsukrovym diabetom 2-ho typu zalezhno vid rivnya insulinemiyi [Features of metabolic parameters in hypertensive patients and in combination with diabetes type 2, depending on the level insulinemiyi]. Buk. med. visnyk. 2013;17(3):176-80. (in Ukrainian).

Chekman IS, Datsyuk NO, Luk’yanova OM. Rol' perekysnoho okyslennya lipidiv u patohenezi arterial'noyi hipertenziyi [The role of lipid peroxidation in the pathogenesis of hypertension]. Liky Ukrayiny. 2008;6:76-81. (in Ukrainian).

Sirenko YuM, Rekovets' OL, Savyts'kyy SYu. Metabolichnyy syndrom u patsiyentiv z arterial'noyu hipertenziyeyu ta metabolichni efekty riznykh antyhipertenzyvnykh preparativ [Metabolic syndrome in patients with hypertension and metabolic effects different antihypertensive drugs]. Arterial. gipertenziya. 2010;4:42-6. (in Ukrainian).

Skrypnyk NV. Kardiometabolichnyy syndrom: vyznachennya, suchasni pohlyady na likuvannya [Kardiometabolichnyy syndrome: definition, current views on treatment]. Hal. likar. visnyk. 2008;15(4):113-19. (in Ukrainian).

Talaeva TV, Bratus' VV. Mekhanizmy razvitiya i rol' insulinorezistentnosti v kardial'noy patologii; vozmozhnosti farmakologicheskoy korrektsii [Mechanisms of development and the role of insulin resistance in cardiac pathology; capabilities pharmacological correction]. Ukr. kardiol. zh. 2006;2:116-22. (in Russian).

Shalimova AS. Endotelial'na dysfunktsiya ta yiyi korektsiya u patsiyentiv z hipertonichnoyu khvoroboyu i tsukrovym diabetom 2-ho typu [Endothelial dysfunction and its correction in patients with hypertension and diabetes diabetes type 2]. Mizhnar. endokrynol. zhurnal. 2014;2:33-9. (in Ukrainian).

American Diabetes association. Standards of medical care in diabetes. Diabetes Care. 2008;31:12-54.

Antuna-Puente B, Fevers B, Fellah JP. Bastard Adipokines: The missing link between insulin resistance and obesity. Diabetes. Metabolism. 2008;34(1):2-11.

Bergman RN. Insulin Resistance: Insulin Action and Its Disturbances in Disease. N. Engl. J. Med. 2005;353:2201-09.

Bloomgarden ZT. Concepts of insulin resistance. Metab. Syndr. Relat. Disord. 2005;3(4):284-93.

Chauhan A. Hyperinsulinemia, coronary artery disease and syndrome X. J. Amer. Coll. Cardiology. 1994;29:364-69.

Chin J, Azhar S, Hoffman B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. Clin. Invest. 1992;89:10-18.

Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Arch. Intern. Med. 2009;169(Suppl. 2):155-62.

Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-98.

Gianturco V, Bellomo A, D’Ottavio E. Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? Arch. Gerontol. Geriatr. 2009;(Suppl.49):129-33.

Montecucco F, Pende A, Quercioli A. Inflammation in the pathophysiology of essential hypertension. J. Nephrol. 2011;24:23-4.

Mancia G, Bombelli M, Corrao G. Metabolic syndrome in the Pressioni Arteripse Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertens. 2007;49:40-7.

Dandona P, Aljada A, Chaudhuri A. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-54.

Paolisso G, Galderisi M, Tagliamonte MR. Myocardial wall thickness and left ventricular geometry in hypertensives. Relationship with insulin. Am. J. Hypertens. 1997;10:1250-56.

Zavaroni I, Mazza S, Dall E. Aglio Prevalence of hyperinsulinaemia in patients with high blood pressure. J. Intern. Med. 1992;231(3):235-40.

Borona E, Kiechl S, Willeit J. Prevalence of insulin resistance in metabolic disorders. Diabetes. 1998;47:1643-48.

Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome. Diabetes Care. 2004;27(4):1011-12.

Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121-31.

Graham TE, Yang Q, Bluher M. Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects. N. Engl. J. Med. 2006;354(24):2552-63.

Ramakrishnan SN, Lau P, Burke LJ. Reverbbeta regulates the expression of genes involved in lipid absorption in skeletal muscle cells: evidence for cross-talk between orphan nuclear receptors and myokines. J. Biol. Chem. 2005;280(10):8651-59.

Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007;92(2):379-85.

Savage D, Petersen KF, Shuiman GI. Mechanisms of insulin resistance in human and possible links with inflammation. Hypertension. 2005;45:828-36.

Smith DO, Roith DLe. Insulin resistance syndrome, prediabetes, and the prevention of type 2 diabetes mellitus. Clin. Cornerstone. 2004;6(2):7-16.

Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium–dependent relaxation by activating protein kinase C. J. Clin. Invest. 1991;87:1643-48.

Hammarstedt A, Andersson CX, Rotter Sopasakis V. The effect of PPARγ ligands on the adipose tissue in insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2005;73(1):65-75.

Saely CH, Aczel S, Marte T. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients. J. Clin. Endocrinol. Metab. 2005;90(10):5698-703.


Посилання

  • Поки немає зовнішніх посилань.


Copyright (c) 2017 S. V. Biletskyi

Технічний редактор журналу, к.мед.н. М. Степанченко, 2015-2017